BUZZ-Clovis Oncology's lung cancer drug can compete with AstraZeneca's - analysts
** Cancer drug developer's shares up 18 pct at $99.71 on strong data on experimental lung cancer drug
** Stock had earlier touched $100.82, crossing the $100 mark for only the 2nd time ever; life high was $102.28 on May 14
** Clovis presents data on lung cancer drug rociletinib, which, analysts say, show that the drug can compete effectively against AstraZeneca Plc (NYSE: AZN - news) 's AZD9291
** AstraZeneca's AZD9291 targets the same mutation in lung cancer patients; AstraZeneca down 0.7 pct
** Mizuho Securities says differentiating factor in favor of Clovis' rociletinib is that drug's efficacy did not depend on the cancer spreading to the central nervous system
** Up to Tuesday's close, stock had risen fallen 17.5 pct since touching the record high on May 14